Karyopharm Therapeutics announces initiation of Phase I study of Selinexor in Singapore
Selinexor (KPT-330), is a first-in-class, oral selective inhibitors of nuclear export (SINE) compound that covalently inhibits exportin-1 (XPO1/CRM1), which leads to the accumulation of tumor suppressor proteins in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.